Organically Modified Silica Nanoparticles Coencapsulating Photosensitizing Drug and Two-Photon Absorber for Two-photon Activated Photodynamic Therapy

Photodynamic therapy (PDT), following health agency approvals throughout the world for various cancers and other diseases, is slowly being accepted as a standard treatment for the treatment of obstructive esophageal and lung cancers as well as e arly stage lung cancer, and actinic keratoses. However, the hydrophobic nature of most photosensitizing drugs makes the preparation of pharmaceutical formulations for parenteral administration very difficult.

This technology explains the for mulation of a nanosized drug delivery carrier and the method of delivering photodynamic drugs, which are free from the external agents. From the results obtained for significant photosensitizing efficacy in vitro and in vivo conditions, it is believe d that upon administration for photodynamic therapy use in humans, the drug will interact with human serum albumin or other intracellular molecules for allowing the recovery of fluorescence

Categories: Nanotechnology, Therapeutic and Vaccines

Type of Offer: Licensing



« More Nanotech Patents
« More Pharmaceutical Patents

---